Author

Chai Discovery Team

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 1 Synthetic Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 2 Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Research Focus:software / tool· 2 Research Focus:protein design· 1 Assay:protein sequence· 1 Assay:protein structure· 1 Approach:statistical model· 1

Frequent Co-Authors

Alex RogozhnikoviD· 2 shared Danny Geisz· 2 shared Jack Dent· 2 shared Jacques BoitreaudiD· 2 shared Joshua MeieriD· 2 shared Kevin WuiD· 2 shared Matt McPartloniD· 2 shared Nathan Rollins· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Alex RogozhnikovORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Drug-like antibody design against challenging targets with atomic precision

Chai Discovery Team, Jacques Boitreaud, Robert S. Chen, Jack Dent, Lucy Fairweather, Danny Geisz, Matthew Greenig, Nate Boyd, Jinay Jain, Brady Johnston, Matt McPartlon, Joshua Meier, Neil Patil, Zhuoran Qiao, Alex Rogozhnikov, , Andy Yeung

This paper introduces a computational antibody design platform that generates drug-like antibodies with high developability and atomic accuracy, demonstrating its utility for challenging therapeutic targets.

bioRxiv · Nov 29, 2025 · PreprintMolecular Biology

Zero-shot antibody design in a 24-well plate

Chai Discovery Team, Jacques Boitreaud, Jack Dent, Danny Geisz, Matt McPartlon, Joshua Meier, Zhuoran Qiao, Alex Rogozhnikov, Nathan Rollins, Paul Wollenhaupt, Kevin Wu

This paper introduces Chai-2, a model that designs antibodies with a 16% hit rate, achieving success in 50% of targets without prior binders, and enables rapid validation in under two weeks.

bioRxiv · Jul 5, 2025 · PreprintSynthetic Biology